Form 4: Enanta Pharmaceuticals Chief Business Officer Reports Stock Transactions
SEC Form 4 Filing
Brendan Luu, Chief Business Officer of Enanta Pharmaceuticals, reports acquisition of 7,500 shares and disposal of 3,326 shares of common stock on February 12, 2025.
Summary
- On February 12, 2025, Brendan Luu, the Chief Business Officer of Enanta Pharmaceuticals, acquired 7,500 shares of common stock due to the vesting of performance share units (PSUs).
- These PSUs vested based on the achievement of two-year research and development milestones in the 2023-2024 period, as determined by Enanta's Compensation Committee.
- Concurrently, Luu disposed of 3,326 shares to cover withholding taxes related to the PSU settlement at a price of $5.59 per share.
- Following these transactions, Luu directly owns 40,221 shares of Enanta Pharmaceuticals common stock.
Sentiment
Score: 6
Explanation: Neutral sentiment as the filing reflects routine stock transactions related to executive compensation and tax obligations.
Positives
- The vesting of performance share units indicates the achievement of research and development milestones, which is a positive sign for the company's progress.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and provide transparency to the market regarding the actions of company executives.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
Key Dates
| Date | Description |
|---|---|
| 02/12/2025 | Date of stock acquisition and disposal. |
| 02/14/2025 | Date of signature by attorney-in-fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.